Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of TQG203 in Hemophilia with Inhibitors
NCT04768699Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Pharmacokinetic assessment (Plasma Concentration) at 24 hours, Activated Partial Thromboplastin Time at 24 hours and 1 more. Status: unknown.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04768699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768699.